NCT07036848 Efficacy and Safety of Surgical Treatment for Type IVa CBD
| NCT ID | NCT07036848 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tsinghua Chang Gung Hospital |
| Condition | Choledochal Cyst |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2025-07-14 |
| Primary Completion | 2025-07-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2025-07-14 with a primary completion date of 2025-07-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa biliary dilatation (BD). Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.
Eligibility Criteria
Inclusion Criteria: 1. Patients who have been diagnosed with Todani type IVa BD. 2. Patients aged between 0 and 80 years old, regardless of gender. 3. First-time receipt of surgery. Exclusion Criteria: 1. With abnormal intrapancreatic bile duct 2. Inappropriate Roux-loop length (outside the range of 40-60 cm for adults and 15-30 cm for children) 3. With non-relevant surgical interventions 4. Pathologically confirmed carcinogenesis 5. Unresolved choledocholithiasis, bile duct stenosis, and Intrahepatic bile duct stones during the procedure. 6. Unavailable follow-up information.
Contact & Investigator
Shuo Jin, PhD
PRINCIPAL INVESTIGATOR
Beijing Tsinghua Changgeng Hospital
Frequently Asked Questions
Who can join the NCT07036848 clinical trial?
This trial is open to participants of all sexes, up to 80 Years, studying Choledochal Cyst. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07036848 currently recruiting?
Yes, NCT07036848 is actively recruiting participants. Contact the research team at ycz23@mail.tsinghua.edu.cn for enrollment information.
Where is the NCT07036848 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07036848 clinical trial?
NCT07036848 is sponsored by Beijing Tsinghua Chang Gung Hospital. The principal investigator is Shuo Jin, PhD at Beijing Tsinghua Changgeng Hospital. The trial plans to enroll 1,500 participants.